[Featured Stock] Incon Rises on Johnson & Johnson COVID-19 Vaccine Domestic Introduction Review

[Asia Economy Reporter Minwoo Lee] Incon's stock price is rising on news that the government is considering introducing Johnson & Johnson's novel coronavirus (COVID-19) vaccine.

As of 3:03 PM on the 27th, Incon's stock price recorded 3,790 won, up 27.61% from the previous day. The news that the government is considering the introduction of Johnson & Johnson's COVID-19 vaccine and that it has previously recruited an expert who was a former vice president of Johnson & Johnson appears to have been highlighted.

On the 14th of last month, the government shared vaccine development information with Johnson & Johnson and began purchase negotiations. It is known that Johnson & Johnson demanded a final contract with the Korean government within six weeks. Therefore, it is speculated that the contract may have already been finalized on the 25th.

Johnson & Johnson's vaccine aims to complete approval from the U.S. Food and Drug Administration (FDA) by the end of February next year, which aligns with the Korean government's goal of starting initial vaccinations in the second quarter. The government plans to announce the exact vaccine type and quantity early next month.

Meanwhile, Incon's U.S. subsidiary, Zyversa Therapeutics, has recruited Jules Muizing, who served as global marketing vice president at Johnson & Johnson last year, as chairman of the board. Additionally, experts responsible for immunology research and development at Johnson & Johnson have reportedly been appointed as key executives.